<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717858</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-4192</org_study_id>
    <secondary_id>2014-004772-38</secondary_id>
    <secondary_id>U1111-1163-4641</secondary_id>
    <nct_id>NCT02717858</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the effects of
      liraglutide on gallbladder emptying in overweight and obese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2016</start_date>
  <completion_date type="Actual">February 27, 2017</completion_date>
  <primary_completion_date type="Actual">February 27, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum postprandial gallbladder ejection fraction (GBEFmax)</measure>
    <time_frame>At 12 weeks (visit 9)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GBEFmax (maximum gallbladder ejection fraction) after first treatment dose</measure>
    <time_frame>At first treatment dose (visit 4, day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder volume</measure>
    <time_frame>At first dose (visit 4, day2),after 12 weeks (visit 9, day 85)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder volume</measure>
    <time_frame>At 12 weeks (visit 9)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under gallbladder EF-time (ejection fraction) curve</measure>
    <time_frame>At first dose (visit 4, day 2),after 12 weeks (visit 9, day 85)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under gallbladder EF-time curve</measure>
    <time_frame>At 12 weeks (visit 9)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the paracetamol concentration-time curve</measure>
    <time_frame>At first dose (visit 4,day 2) after 12 weeks (visit 9, day 85)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the paracetamol concentration-time curve</measure>
    <time_frame>At 12 weeks (visit 9)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental area under the plasma glucose concentration-time curve</measure>
    <time_frame>At first dose (visit 4,day 2) after 12 weeks (visit 9, day 85)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental area under the plasma glucose concentration-time curve</measure>
    <time_frame>At 12 weeks (visit 9)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Injected s.c./subcutaneously (under the skin) once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-64 years (both inclusive) at the time of signing informed
             consent

          -  Body mass index (BMI) equal to or above 27.0 kg/m^2

          -  Stable body weight (less than 3 kg self-reported change during the previous 3 months)

          -  Ultrasound assessment of gallbladder volume of an acceptable quality at screening, as
             judged by the investigator

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using adequate contraceptive methods (intrauterine
             devices or hormonal contraception (oral contraceptive pills, implants, transdermal
             patches, vaginal rings or longacting injections))

          -  History of gastrointestinal surgery or other medical procedure precluding gallbladder
             emptying assessment (appendectomy is allowed) or any significant digestive disease per
             the judgement of the investigator

          -  History of pancreatitis (acute or chronic) or any gallbladder disease (incl.
             gallstones, gallbladder sludge, or polyps)

          -  Any disorder which in the investigator's opinion might jeopardise subject's safety or
             compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

